Atrial Fibrillation Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2032

1.1 AF market will decline at a negative CAGR of 1.3%
1.2 Bayer and Bristol Myers Squibb will continue to lead the AF market over the forecast period
1.3 While outlook in AF improves, opportunities remain to improve patient outcomes
1.4 Bayer’s FXIa inhibitor asundexian will be a key driver of growth
1.5 What do physicians think?

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3.1 Etiology and pathophysiology
3.2 Classification

4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 8MM Forecast Methodology
4.5 Epidemiological Forecast for atrial fibrillation
4.6 Discussion

5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management

6.1 Overview

7.1 Overview
7.2 Development of anticoagulants with reduced risk of bleeding
7.3 Therapies for atrial fibrillation patients with ESRD
7.4 Safer antiarrhythmic drugs for the maintenance of sinus rhythm
7.5 Effective and rapid-acting cardioversion drugs

8.1 Overview
8.2 Clinical trials design

9.1 Overview
9.2 Promising drugs in clinical development

10.1 Overview
10.2 Competitive assessment

11.1 Overview
11.2 Deal-making trends

12.1 Global markets
12.2 US
12.3 5EU
12.4 Japan
12.5 Canada

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.4 Primary research - KOLs interviewed for this report
13.5 Primary research - prescriber survey
13.6 About the Authors

• Contact the Publisher

Table 1: Atrial fibrillation: key metrics in the 8MM
Table 2: Common cardiac and non-cardiac causes of AF
Table 3: Classification of AF
Table 4: Risk factors and comorbidities for AF
Table 5: CHADS2 index for stroke risk assessment
Table 6: CHA2DS2-VASc index for stroke risk assessment
Table 7: Treatment guidelines for atrial fibrillation
Table 8: Atrial fibrillation market - global drivers and barriers, 2022-32
Table 9: Key events impacting sales for atrial fibrillation in the US, 2022-32
Table 10: Atrial fibrillation market - drivers and barriers in the US, 2022-32
Table 11: Key events impacting sales for atrial fibrillation in the 5EU, 2022-32
Table 12: Atrial fibrillation market - drivers and barriers in the 5EU, 2022-32
Table 13: Key events impacting sales for atrial fibrillation in Japan, 2022-32
Table 14: Atrial fibrillation market - drivers and barriers in Japan, 2022-32
Table 15: Key events impacting sales for atrial fibrillation in Canada, 2022-32
Table 16: Atrial fibrillation market - drivers and barriers in Canada, 2022-32
Table 17: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for atrial fibrillation in 2022 and 2032
Figure 2: Analysis of the company portfolio gap in atrial fibrillation during the forecast period
Figure 3: Competitive assessment of the pipeline anticoagulant drugs benchmarked against the current SOC
Figure 4: Competitive assessment of the pipeline drugs for pharmacological cardioversion benchmarked against the SOC
Figure 5: 8MM, diagnosed prevalence of AF (%), men and women, ages =40 years, 2022
Figure 6: 8MM, sources used and not used to forecast the diagnosed prevalent cases of AF
Figure 7: 8MM, sources used to forecast the diagnosed prevalent cases of AF by temporal pattern of arrhythmia
Figure 8: 8MM, sources used to forecast the diagnosed prevalent cases of AF by CHADS2 stroke risk score
Figure 9: 8MM, sources used to forecast the diagnosed prevalent cases of AF by CHA2DS2 - VASc score in men
Figure 10: 8MM, sources used to forecast the diagnosed prevalent cases of AF by CHA2DS2 - VASc score in women
Figure 11: 8MM, sources used to forecast the diagnosed prevalent cases of AF with/without moderate-to-severe mitral stenosis and/or an artificial (mechanical) heart valve
Figure 12: 8MM, sources used to forecast the diagnosed prevalent cases of AF with CKD
Figure 13: 8MM, sources used to forecast the diagnosed prevalent cases of AF with major bleeding risk by HAS-BLED score
Figure 14: 8MM, sources used to forecast the diagnosed prevalent cases of AF admitted to the ED
Figure 15: 8MM, sources used to forecast the diagnosis rate of AF
Figure 16: 8MM, total prevalent cases of AF, N, both sexes, ages =40 years, 2022
Figure 17: 8MM, diagnosed prevalent cases of AF, N, both sexes, ages =40 years, 2022
Figure 18: 8MM, diagnosed prevalent cases of AF by age, N, both sexes, 2022
Figure 19: 8MM, diagnosed prevalent cases of AF by sex, N, ages =40 years, 2022
Figure 20: 8MM, diagnosed prevalent cases of AF by temporal pattern of arrhythmia, N, both sexes, ages =40 years, 2022
Figure 21: 8MM, diagnosed prevalent cases of AF by CHADS2 stroke risk score, N, both sexes, ages =40 years, 2022
Figure 22: 8MM, diagnosed prevalent cases of AF by CHA2DS2 - VASc stroke risk score in men, N, men, ages =40 years, 2022
Figure 23: 8MM, diagnosed prevalent cases of AF by CHA2DS2 - VASc stroke risk score in women, N, women, ages =40 years, 2022
Figure 24: 8MM, diagnosed prevalent cases of AF with and without moderate-to-severe mitral stenosis and/or an artificial (mechanical) heart valve, N, both sexes, =40 years, 2022
Figure 25: 8MM, diagnosed prevalent cases of AF with CKD by stage, N, both sexes, ages =40 years, 2022
Figure 26: 8MM, diagnosed prevalent cases of AF by HAS-BLED score, N, both sexes, ages =40 years, 2022
Figure 27: 8MM, diagnosed prevalent cases of AF admitted to ED, N, both sexes, ages =40 years, 2022
Figure 28: General treatment algorithm for stroke prevention in AF
Figure 29: CCS guideline recommendations for choosing an anticoagulant
Figure 30: General treatment algorithm for long-term ventricular rate control in AF patients
Figure 31: Treatment algorithm for the maintenance of sinus rhythm in AF patients
Figure 32: Unmet needs and opportunities in AF
Figure 33: Overview of the development pipeline in atrial fibrillation
Figure 34: Key late-stage trials for the promising pipeline agents that the publisher expects to be licensed for atrial fibrillation in the 8MM during the forecast period
Figure 35: Competitive assessment of the marketed and pipeline drugs for anticoagulation benchmarked against the SOC
Figure 36: Competitive assessment of the marketed and pipeline drugs for pharmacological cardioversion benchmarked against the SOC
Figure 37: Analysis of the company portfolio gap in AF during the forecast period
Figure 38: Global (8MM) sales forecast by country for atrial fibrillation in 2022 and 2032
Figure 39: Sales forecast by class for atrial fibrillation in the US in 2022 and 2032
Figure 40: Sales forecast by class for atrial fibrillation in the 5EU in 2022 and 2032
Figure 41: Sales forecast by class for atrial fibrillation in Japan in 2022 and 2032
Figure 42: Sales forecast by class for atrial fibrillation in Canada in 2022 and 2032